OR WAIT null SECS
© 2021 MJH Life Sciences and Endocrinology Network. All rights reserved.
© 2021 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
August 02, 2021
July 31, 2021
July 29, 2021
How Recent Developments Impact Insulin Affordability
July 28, 2021
The National Kidney Foundation released a position statement on July 27 providing new guidance related to kidney transplants in the US.
July 27, 2021
An analysis of a subset of patients from the STAMPEDE trial provides new evidence detailing the quality of life improvements associated with undergoing bariatric surgery in patients with uncontrolled type 2 diabetes.
A study from the University of South Australia assessing the impact of high-dose, short-term caffeine consumption suggests increased consumption could increase renal calcium clearance by 77% in healthy patients.
July 26, 2021
A systematic review and meta-analysis of randomized trials suggest use of physical activity trackers, such as pedometers and accelerometers, were linked to increased levels of physical activity versus non-use in patients with cardiometabolic conditions.
July 23, 2021
With approval, exenatide extended-release (BYDUREON BCise) becomes the first weekly GLP-1 RA therapy to receive approval for improving glycemic control in pediatric patients aged 10-17 years with type 2 diabetes.
July 22, 2021
Analysis of more than 18 million pregnancies sheds light on the impact various prepregnancy cardiovascular risk factors, including BMI, smoking status, and diabetes, can have on risk of adverse maternal and fetal outcomes.
Using data from more than 2000 patients followed for 16 years, a Garvan Institute of Medical Research-led team found cognitive decline in older women could help predict bone loss and fracture risk among these patients.
July 21, 2021
While tenapanor has already received approval for treatment of abdominal pain in patients with IBS, the US FDA issued a letter to Ardelyx noting deficiencies in their NDA for an indication related to controlling serum phosphorus in adult patients with CKD on dialysis “preclude discussion” related to labeling and post-marketing requirements.
July 20, 2021
A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.
July 19, 2021
Data from a phase 2 study of women with overweight or obesity and polycystic ovary syndrome suggests use of licogliflozin was associated with significant reductions in hyperinsulinemia and androgenemia in this patient population.